Although a substantial body of literature describes the occurrence and clinical consequences of atherosclerotic coronary vascular disease (ASCVD) in patients with end stage renal diseases (ESRD), the prevalence and outcomes of vascular disease in other arterial beds is not well-characterized. Peripheral vascular disease (PVD) is especially germane for scrutiny because of its apparent greater prevalence in ESRD patients (1, 2) , the perceived disproportionate use of amputation as the therapeutic option (3) , and the poor survival of ESRD patients with PVD (4, 5) Estimating the prevalence of PVD in the ESRD population is difficult largely due to non-uniformity of disease definition and diagnostic methods. Several reporting strategies have been used to quantitate the prevalence of PVD in the general population and those with ESRD. The prevalence of PVD in the general population has been defined based on clinical symptoms such as intermittent claudication. In healthy men without cardiovascular or renal disease aged 40-65 years old, the prevalence of claudication is approximately 2.7% (2) . Using World Health Organization (WHO) criteria for PVD and ankle-brachial pressure index measurements, the prevalence of peripheral arterial occlusive disease inclusive of intermittent claudication and asymptomatic cases in the general population is 6.9% (6) . In contrast, in the absence of corroborating clinical or radiological data, the 2001 USRDS Annual Data Report describes a PVD incidence of 14.8% in patients of mean age 60 years old incident to dialysis in 1998 (1) . Reporting and categorical bias is likely because of limitations in data collection. Another report of the prevalence of PVD in ESRD patients uses non-traumatic limb amputation as a surrogate for severe PVD. Eggers et al, examined hospital billing data of Medicare dependent ESRD patients coded for amputations in 1994. It was reported that 4.3 amputations per 100 persons were performed in 1991 with a significant increase to 6.2 in l994 (4) . It is apparent that the less inclusive diagnostic criteria used for reporting of PVD in the ESRD population are likely to result in underestimation of the true prevalence.
Revascularization for PVD entails two primary interventions: surgical reconstruction using either autologous veins or artificial grafts and percutaneous angioplasty. Advocates for surgical revascularization as the preferred treatment modality for ESRD patients describe acceptable graft patency (7) , limb salvage (8) , and peri-operative mortality rates (7, 9, 10) . These findings have been demonstrated in several retrospective, uncontrolled case series and case control studies that have reported graft patency, limb salvage and patient survival rates at 2 years of between 35-90%, 45-91%, and 35-65%, respectively (5, 7-9, 11-14) (Tab. I). Interpretative limitations include the likelihood of patient selection bias, i.e. only patients deemed suitable for vascular reconstruction and likely to enjoy its benefits are captured and reported. Moreover, the small numbers of patients make random events more difficult to dismiss. The external validity of these reports is limited by the limited numbers of clinical centers and the propensity of these to be single center reports. Possible reporting bias exists because of the tendency to publish only favorable clinical results. Last, even if the outcome results are non-random and the findings externally applicable, the patients' postoperative residual functional status are not reported. Arguably, the absence of such information dilutes the interpretation of an important practicable measure of success that has been used regularly in studies in the general population (15, 16) .
In 1996, a systematic review of the various outcome studies of revascularization in ESRD patients with PVD, demonstrated overall graft patency, limb salvage and survival rates at 2 years to be 67%, 70% and 51%, respectively, using adjusted life-table methods (17) . Comparatively, an uncontrolled case series involving 243 non-ESRD patients reported graft patency and limb salvage rates at 2 years of 92% and 89%, respectively (18) . In 2001, a case control study showed that non-ESRD patients with PVD undergoing surgical revascularization had better results (limb salvage, graft patency and survival) compared to age, gender, and race matched ESRD patients (5) . It is unclear if the apparent disparity in clinical effectiveness of revascularization is a consequence of differences in patient case mix, timing of patient referral, relative ineffectiveness of surgical revascularization, or inherent underlying morbidity and mortality of the ESRD population. Although a metaanalyses of mortality, graft patency and limb salvage rates following bypass surgery in the general population found no better results in comparison to other treatment modalities (19) , this finding has not been determined in the ESRD population yet.
Studies that examined percutaneous coronary angioplasty in ESRD patients on haemodialysis have shown good initial coronary vessel patency rates but are limited by high restenosis rates (20, 21) . Unfortunately, studies examining angioplasty use on lower extremity PVD in ESRD patients have been inconsistent and limited. Coupled with accelerated atherosclerosis in ESRD patients (22, 23) the current bias seems to be towards surgical therapy as this may be perceived as more definitive.
Because of the general impression that revascularization procedures in ESRD patients are associated with poorer outcome indifferent of the clinical definition, primary amputation has been advocated by some as the treatment of choice in ESRD patients, especially if PVD is complicated by infection or gangrene (11, 12, 24) . There are two points of advocacy for primary amputation in ESRD patients with PVD. Firstly, a large majority of ESRD patients with PVD have co-morbidities that contribute to higher baseline mortality (25) , and this may render them higher risk candidates for extensive revascularization surgery (26) . Second, failure of primary limb salvage procedures is associated with mortality (24) . Despite this chain of logic advocating for primary lower extremity amputation, reported survival rates for ESRD patients after amputation have been dismal with rates of 49.3% at 1 year decreasing to 37.2% at 2 years (4). Hospital mortality rates are high at 24%, when compared to a non-FSRD group matched for similar above and below knee amputations (27) . primary amputation. Overall 5 year patient survival for the bypass group was 40% compared to 9% for the amputation group (28) . However, both groups had reduced survival compared to patients with normal kidney function. It is unclear if patients were selected for revascularization because of the preoperative likelihood of better outcomes and vice versa.
Improved quality of life (29) and functional status (30) following revascularization in the general population have supported its role as the primary mode of treatment. These benefits have not been replicated in the ESRD population. Patients on maintenance hemodialysis often have associated psychosocial problems in addition to physical de-conditioning (31) and malnutrition (32) (33) (34) . Significantly, depression in ESRD patients is associated with mortality risk (35) . Any form of surgical intervention may serve to precipitate or worsen these problems and should be considered carefully in selection of the best treatment. Amputation may not be the best treatment modality in these patients as they will be wheelchair dependent or bed bound post-procedure, thus further diminishing their quality of life and deepening existing depression. Lower extremity amputations and the subsequent use of prostheses are associated with increased energy expenditure of up to 60%, (36, 37) , and so may increase the risk of worsening nutrition. Costs of caring for such patients may also increase secondary to loss of mobility. Such functionally dependent patients also place increased demands on the dialysis personnel caring for them in terms of increased manpower hours with higher nurse to patient ratios (38) .
Cost analysis of revascularization or amputation as primary modalities of treatment have yielded inconsistent results. It has been estimated that the average hospital cost of limb salvage per year in ESRD patients with PVD was $44,308 (26) . However, when compared to non-ESRD patients undergoing surgical revascularization, mean hospital per-procedure charges (excluding dialysis charges) were lower in ESRD patients (5) . Retrospective case control and prospective cohort studies in non-ESRD populations have also shown successful revascularization to be less costly when compared to amputation (39, 40) . Part of the reason for the apparent increased cost of amputation can be attributed to the need for more extensive care and rehabilitation post-amputation (40) . The inconsistency of these cost-analyses results could also be a reflection on the fact that the studies did not adjust for differences in reimbursement levels between health care delivery systems.
Several opportunities for clinical research are herein identified. The incidence and prevalence of PVD in chronic kidney disease and ESRD needs greater clarification. Angioplasty as a primary modality of treatment has not been well explored. This is particularly appropriate when seen in the context of ESRD patients being high risk candidates for surgical procedures. In addition, the prohibitive costs of surgical procedures could further augment a role for lower cost angioplasty treatment. Arguably, a randomized controlled trial might be the most appropriate instrument for comparing outcomes following amputation or revascularization. These appear to be issues without an evidence-based solution. Nevertheless, physicians caring for ESRD patients with PVD have to make therapeutic decisions on amputation versus revascularization. Current evidence is neither strong nor consistent favoring one procedure over another. 
